The Bryan Johnson Stack
Blueprint founder Bryan Johnson's publicly documented four-week CJC-1295 DAC + tirzepatide self-experiment, with his measurement protocol. Cited from his Apr 21 2026 post.
Source post ↗The public protocol
Johnson posted the full protocol on X on 21 April 2026. This page is a read-only companion — it records what he published, in his own words where possible, and maps each compound to current prices. Johnson is not endorsing Pepwizard; we're citing his public experiment so buyers working from his data can find the underlying peptides at the best price.
The frame
"Everyone's injecting peptides. Almost no one is measuring what they actually do."
His hypothesis: two peptides with opposite autonomic and glucose vectors can be stacked so the side effects cancel while the upside compounds.
- CJC-1295 DAC (GHRH agonist) — growth, repair, sustained IGF-1 elevation. Can blunt glucose control and raise insulin resistance.
- Tirzepatide (dual GIP/GLP-1) — metabolic optimisation, appetite suppression. Raises resting HR; can disrupt sleep.
Opposite vectors on autonomic tone. Opposite vectors on glucose. On paper, the side effects cancel but the benefits don't.
The four-week dose schedule
| Week | CJC-1295 DAC | Tirzepatide |
|---|---|---|
| 1 | 1.2 mg | — |
| 2 | 2.4 mg (or switch to no-DAC + ipamorelin daily if side effects demand) | — |
| 3 | 2.4 mg weekly | 0.25 mg, twice weekly |
| 4 | 2.4 mg weekly | 0.25 mg, twice weekly |
Johnson notes DAC peptides are long-acting, so he is deliberately titrating low.
The measurement stack
What Johnson is tracking across all four weeks:
- Weekly bloods: IGF-1, GH, GHRH, fasting glucose, insulin, HOMA-IR, ApoA1, ApoB, prolactin, cortisol.
- Continuous CGM across all four weeks.
- Continuous core body temperature via eCelsius capsule, weekly.
- Sleep, HR, HRV — 24/7.
He notes that tirzepatide did not work for him on prior trials: even at 20% of starting dose (0.5 mg/week), his resting HR climbed 2–3 bpm. The current protocol is the experiment to see whether CJC-1295's opposite autonomic signal cancels that.
The DAC vs no-DAC call
Johnson starts with DAC (weekly, long-acting). The peptide community typically leans no-DAC + ipamorelin because it is thought to better preserve pulsatile GH release. Johnson disagrees with the consensus read of the data: he cites sustained GHRH signalling without abolishing pulses, 7.5× overnight GH trough, and >150% IGF-1 increase after two weekly doses at 30 µg/kg as evidence DAC is underrated.
If side effects force a switch, his fallback is no-DAC + ipamorelin, daily, pre-bed.
Buy the compounds at the best price
Below are the peptides Johnson is stacking, with the current cheapest in-stock vendor for each. Pepwizard routes through affiliate links; buying from our cheapest-available vendor is how the site funds its research.
The compounds in this stack
CJC-1295
A synthetic GHRH analogue that stimulates pituitary growth hormone release. The short-acting form (no DAC) is typically paired with a ghrelin agonist like ipamorelin.
Tirzepatide
A dual GIP and GLP-1 receptor agonist producing the largest sustained weight reductions of any drug currently licensed, averaging 20–22% body weight loss in clinical trials.
Ipamorelin
A selective growth hormone secretagogue that stimulates pulsatile GH release from the pituitary without significantly affecting cortisol, prolactin, or appetite.